David A. Siegel Viking Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,091,428 shares of VKTX stock, worth $43.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

1,091,428

Holding current value

$43.5 Million

% of portfolio

0.06%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$19.98 - $29.49 $21.8 Million - $32.2 Million	1,091,428 New	1,091,428 $28.9 Million
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $116,057 - $170,048	10,628 New	10,628 $117,000
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $408,040 - $875,164	-50,500 Reduced 5.33%	896,528 $14.9 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $109,888 - $379,760	40,400 Added 4.46%	947,028 $8.9 Million
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $546,720 - $834,016	-214,400 Reduced 19.13%	906,628 $2.47 Million
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $27,430 - $40,950	13,000 Added 1.17%	1,121,028 $3.24 Million
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $688,800 - $1.12 Million	229,600 Added 26.14%	1,108,028 $3.32 Million
Q4 2021 Feb 14, 2022	SELL	$4.6 - $6.72 $277,840 - $405,888	-60,400 Reduced 6.43%	878,428 $4.04 Million
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $253,332 - $319,616	-45,400 Reduced 4.61%	938,828 $5.9 Million
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $217,980 - $282,660	-42,000 Reduced 4.09%	984,228 $5.9 Million
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $3.23 Million - $5.44 Million	562,700 Added 121.4%	1,026,228 $6.49 Million
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $2.02 Million - $2.56 Million	382,000 Added 468.55%	463,528 $2.61 Million
Q3 2020 Nov 16, 2020	BUY	$5.73 - $8.11 $240,820 - $340,847	42,028 Added 106.4%	81,528 $474,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $171,825 - $319,160	39,500 New	39,500 $285,000
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $101,572 - $133,196	-13,400 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $134,608 - $304,748	-18,800 Reduced 58.39%	13,400 $103,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $77,600 - $157,200	8,000 Added 33.06%	32,200 $561,000
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $20,952 - $68,796	5,400 Added 28.72%	24,200 $230,000
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $77,268 - $130,284	18,800 New	18,800 $82,000

Others Institutions Holding VKTX

# of Institutions

448

Shares Held

66.9M

Call Options Held

7.9M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.06B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account